According to a recent study, in patients with frontotemporal dementia (FTD), epileptic seizures are significantly more common than previously known. The discovery deepens understanding of the symptoms ...

A study led by Monash University and believed to be a world first has demonstrated that an Artificial Intelligence (AI) model can potentially predict the best personalized, anti-seizure medication for ...

A new 16-week study of 204 adult epilepsy patients found that 98% of participants believe that all patients with epilepsy should have a seizure action plan (SAP), regardless of seizure status. These ...

EpilepsyGTx, a biotechnology company developing gene therapies for refractory epilepsy, and Viralgen, a leading contract ...

A significantly higher proportion of patients with epilepsy scored above the threshold for clinically significant insomnia compared with controls in this new analysis, in line with previous research.

After he was diagnosed with “silent” epileptic seizures, doctors were able to treat his memory loss and confusion.

Neuroelectrics is developing therapies that it says will improve the lives of people living with brain disease. The Barcelona-based start-up's main product is a headcap, which monitors the brain's ...

In this video interview, Amélie Lothe, global medical community head for rare epilepsies at UCB Pharma, explains why the full ...

Nine years ago, a patient in Kisumu requiring specialised brain or spine surgery had few options but to travel to Nairobi or, for those who could afford it, seek treatment outside the country. Kisumu ...

A next-generation brain implant currently in clinical use for treating refractory epilepsy -- to help prevent symptoms including seizures -- does not induce changes to patients' personalities or ...

BENIN, Nigeria, Mar 19 2025 (IPS) - When Angela Asemota’s son began having seizures at six years old in 1996, people gossiped that he was possessed by evil spirits, leading her to seek healing from ...

EpilepsyGTx, a biotechnology company developing gene therapies for refractory epilepsy, and Viralgen, a leading contract ...